They hypothesized that the expression of VEGF is not regulated through HER2 in aggressive breast carcinomas, but through other mechanisms such as the expression of hypoxia-inducible factor 1 (HIF-1) in the absence of HER2 overexpression. The gene discussed is ERBB2; the disease is breast carcinoma.